β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease

被引：67

作者：

Andreasen, N ^{[1
]}

Blennow, K

机构：

[1] Huddinge Univ Hosp, Karolinska Inst, Neurotec, Dept Geriatr Med, SE-14186 Stockholm, Sweden

[2] Univ Gothenburg, Dept Clin Neurosci, Unit Neurochem, Gothenburg, Sweden

[3] MRC, Stockholm, Sweden

来源：

PEPTIDES | 2002年 / 23卷 / 07期

关键词：

Alzheimer's disease (AD); beta-amyloid (A beta); biochemical markers; cerebrospinal fluid (CSF); plasma; diagnosis;

D O I：

10.1016/S0196-9781(02)00056-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With the arrival of symptomatic treatment (acetylcholine esterase inhibitors) and the promise of drugs that may delay disease progression, development of diagnostic biomarkers for Alzheimer's disease (AD) are important. beta-Amyloid (Abeta) protein is the main component of senile plaques. A marked reduction in cerebrospinal nuid (CSF)-Abeta42 in AD has been found in numerous studies. Importantly, reduced CSF-Abeta42 is also found very early in the disease process, before the onset of clinical symptoms. Recent studies suggest that CSF-Abeta42 have a satisfactory performance when used as a diagnostic marker for AD in clinical routine. This paper reviews CSF-Abeta42 as a biomarker for AD. (C) 2002 Elsevier Science Inc. All rights reserved.

引用

页码：1205 / 1214

页数：10

共 100 条

[1]

Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109

[2] Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715→Met βAPP-770 mutation responsible for probable early-onset Alzheimer's disease [J].

Ancolio, K ;

Dumanchin, C ;

Barelli, H ;

Warter, JM ;

Brice, A ;

Campion, D ;

Frébourg, T ;

Checler, F .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :4119-4124

[3] Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment [J].

Andreasen, N ;

Minthon, L ;

Vanmechelen, E ;

Vanderstichele, H ;

Davidsson, P ;

Winblad, B ;

Blennow, K .

NEUROSCIENCE LETTERS, 1999, 273 (01) :5-8

[4] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[5] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].

Andreasen, N ;

Minthon, L ;

Davidsson, P ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379

[6] Serpents on the road to dementia and death [J].

Beyreuther, K ;

Masters, CL .

NATURE MEDICINE, 1997, 3 (07) :723-725

[7] Genetic testing for Alzheimer's disease: how close is reality? [J].

Blennow, K ;

Skoog, I .

CURRENT OPINION IN PSYCHIATRY, 1999, 12 (04) :487-493

[8]

BLENNOW K, 1993, ACTA NEUROL SCAND, V88, P221

[9] Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor [J].

Buxbaum, JD ;

Liu, KN ;

Luo, YX ;

Slack, JL ;

Stocking, KL ;

Peschon, JJ ;

Johnson, RS ;

Castner, BJ ;

Cerretti, DP ;

Black, RA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) :27765-27767

[10] EARLY-ONSET ALZHEIMERS-DISEASE CAUSED BY MUTATIONS AT CODON-717 OF THE BETA-AMYLOID PRECURSOR PROTEIN GENE [J].

CHARTIERHARLIN, MC ;

CRAWFORD, F ;

HOULDEN, H ;

WARREN, A ;

HUGHES, D ;

FIDANI, L ;

GOATE, A ;

ROSSOR, M ;

ROQUES, P ;

HARDY, J ;

MULLAN, M .

NATURE, 1991, 353 (6347) :844-846

← 1 2 3 4 5 6 7 8 9 10 →